Nyheter

Antibiotika utan verkan

Vanliga, lätt behandlingsbara infektioner kan snart åter vara dödliga, skriver professor Björn Olsen och smittskyddsläkare Mats Ericsson på UNT Debatt i samband med den europeiska antibiotikadagen. Läs mer »

Bidrag från SciLifeLab för helgenomsekvensering

SciLifeLab har offentliggjort vilka projekt som ingår i Swedish Genome Program och därigenom får bidrag för att utföra helgenomssekvensering. Från IMV är det forskargruppen i molekylär medicin med sitt ALL-projekt som ingår bland de beviljade ansökningarna. Läs pressmeddelandet här.

De ska ta patienter ingen annan vill ha

Ett nytt center ska ta hand om patienter som tror sig ha kronisk borrelia eller som har andra svårdiagnostiserade besvär som skulle kunna komma från fästingar. Läs hela artikeln i Dagens Medicin.

Bror Hjerpstedts Stiftelse

Kawa Amin, Maria Gunnbjörnsdóttir och Andrei Malinovschi har tilldelats medel från Bror Hjerpstedts Stiftelse för forskning inom området astma och allergi. Se beslut.

Kommande disputationer

  • lördag, november 29, 2014 09:00 Auditorium Minus, Gustavianum, Akademigatan 3, Uppsala Kinch, Amelie Posttransplant Lymphoproliferative Disorders: Studies of Epstein-Barr Virus, Regulatory T Cells and Tumor Origin. Ladda ner fulltext Mer information
  • torsdag, december 11, 2014 09:15 Aula Gunnesalen, Ingång 10, Akademiska sjukhuset, Uppsala Alassaad, Anna Improving the Quality and Safety of Drug Use in Hospitalized Elderly: Assessing the Effects of Clinical Pharmacist Interventions and Identifying Patients at Risk of Drug-related Morbidity and Mortality. Ladda ner fulltext Mer information

Aktuella publikationer vid institutionen

  • Strandberg, G., Larsson, A., Lipcsey, M., Eriksson, M. (2011). Intraosseous blood aspirates analysed by a portable cartridge-based device. Critical Care, 15(Suppl 1): 49-49 DOI Mer information
  • Alfredsson, J., Clayton, T., Damman, P., Fox, K., Fredriksson, M. et al. (2014). Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. American Heart Journal, 168(4): 522-529 DOI Mer information
  • Strandberg, G., Eriksson, M., Lipcsey, M., Larsson, A. (2014). Intraosseous Samples Can Be Used for CreatinineMeasurements - An Experimental Study in the Anaesthetised Pig. Clinical Laboratory, 60(10): 1587-1591 DOI Mer information
  • Ruge, T., Carlsson, A., Larsson, T., Carrero, J., Larsson, A. et al. (2014). Endostatin Level is Associated with Kidney Injury in the Elderly: Findings from Two Community-Based Cohorts. American Journal of Nephrology, 40(5): 417-424 DOI Mer information

PIVUS - Prospective Investigation of the Vasculature in Uppsala Seniors

The PIVUS study started in 2001 with the primary aim to investigate the predicive power of different measurements of endothelial function and arterial compliance in a random sample of 1000 subjects aged 70 living in the community of Uppsala. As secondary aims, the study also included measurements of cardiac function and structure by ultrasound and MRI, evaluation of atherosclerosis by ultrasound and MRI, 7 day food intake recordings, detailed ECG analysis, cardiovascular autonomic function, body composition by DXA, DNA analysis and lung function, as well as a number of biochemical markers.

The inclusion of subjects in the study was completed in June 2004 by the team below:

 
          Anna Stenborg, Kerstin Marttala, Lars Lind, Jan Hall

In March 2006 a reinvesigation of the cohort at the age of 75 was started. The major measurements performed at age 70 will be repeated at age 75. In addition, we will focus on infarcts in the brain and heart, so both of these items will be investigated by brain and myocardial MRI in all subjects. Also cognitive tests are included in the reinvestigation that was completed in September 2009.Of the initial 1016 subjects, 52 had died during the 5 years and 827 attended the re-examination at age 75.

In the spring of 2011 we started the 80-year reinvestigation of the cohort. This round will continue until the summer of 2014 and we expect that 500-600 of the original sample will attend. We measure the traditional CV risk factors, 2 cognitive function tests, ultrasound of the carotid arteries and the heart, a DXA scan and an MRI scan of the brain and abdominal region.